UHC Day 2023 - Hepatitis elimination and achieving health for all

Achieving universal health coverage (UHC) means that health care is available to all people everywhere, and this should include hepatitis services. Hepatitis elimination is a key component of UHC, as it strengthens health systems, engages underserved communities, enhances vaccination programmes, reduces cancer mortalities and strengthens HIV responses. 

Significant political will and investment in hepatitis prevention, testing and treatment are needed to achieve both hepatitis elimination and UHC. The United Nations held a High-Level Meeting (HLM) in September 2023 to discuss progress on delivering UHC by 2030. The HLM provides an opportunity to bolster political will for hepatitis elimination through the current global focus on UHC.  

UHC Day is coming up on 12 December!  

This UHC Day, hepatitis advocates must continue to push national governments to uphold the commitments they made at the meeting to hepatitis elimination and UHC. By achieving UHC, people everywhere gain access to essential hepatitis services.  

Get involved towards UHC day 

To support advocacy towards achieving UHC alongside hepatitis elimination, we have developed social media assets to further disseminate the message and call for global action. Download and promote the media assets and help raise awareness across your social media platforms.  

We have also developed a community briefing which outlines the connection between hepatitis elimination and UHC and calls for greater action. This includes calling for the integration of hepatitis elimination into liver cancer services to reduce the burden of NCDs, increasing funding for hepatitis to help achieve UHC, and championing civil society in UHC responses.  

Below is the full communications toolkit which includes social media and email copy to promote with your network.

Webinar: We’re not waiting – viral hepatitis elimination and the new UN Political Declaration on UHC  

WHA hosted a webinar to discuss the United Nations Member States’ recommitment to UHC, why it is relevant to hepatitis elimination and the role of multi-stakeholder responses in achieving both.  

Date: Thursday, 30 November 2023  

Time: 1pm (GMT) 

The webinar is a panel discussion and Q&A session that addressed the following topics:  

  1. What is UHC, the new UN Political Declaration on UHC, and why they are relevant to hepatitis elimination. 
  2. How is UHC being implemented at a country-level? 
  3. Opportunities for hepatitis elimination through UHC, such as NCD integration. 
  4. How hepatitis advocates can work to get the commitments in the UN Political Declaration on UHC implemented locally 

Chair: Cary James, CEO, World Hepatitis Alliance  

Speakers:  

  • Laura Philidor, Advocacy and Communication Officer, CSEM for UHC2030 and WACI Health
  • Maria Eugenia de Feo Moyano, President and Founder, Fundación HCV Salud Sin Fronteras 
  • Devaki Nambiar, Program Director, Healthier Societies Strategy, the George Institute for Global Health India 
  • Rui Tato Marinho MD PHD, Gastroenterologist and Hepatologist, President of National Program for Viral Hepatitis for the Directorate General of Health, Ministry of Health, Portugal 
  • Shaibu Issa, hepatitis B patient advocate, Tanzania 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close